Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Mahan

Neurological Surgery Salt Lake City, UT Medical Doctor

NPI 1477733426 CMS profile 575776

50 N Medical Dr, Salt Lake City, UT 84132

Open in the dashboard

General payments

$698,033

420 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$174,553 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Mark Mahan of Salt Lake City, UT is reported in the CMS Open Payments database as having received $698,033 across 420 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $174,553 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $299,926 173
2024 General $183,337 156
2023 General $29,064 19
2022 General $80,042 34
2021 General $42,283 7
2020 General $22,206 8
2019 General $41,176 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Mahan
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Mark Mahan were reported at $299,926. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Mark Mahan Neurological Surgery median Middle half National median
2019 $41,176 $582 $138–$3,006 $163
2020 $22,206 $294 $76–$2,174 $114
2021 $42,283 $387 $105–$2,432 $132
2022 $80,042 $542 $139–$2,989 $149
2023 $29,064 $534 $145–$2,697 $160
2024 $183,337 $574 $155–$3,046 $164
2025 $299,926 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $399,474 295 payments
  2. Joimax, Inc. $205,670 21 payments
  3. AxoGen $23,426 18 payments
  4. Spineology Inc. $21,036 14 payments
  5. Richard Wolf Medical Instruments Corp. $8,445 1 payment
  6. RIWOspine, Inc. $7,854 2 payments
  7. Pacira Pharmaceuticals Incorporated $6,750 2 payments
  8. SPR Therapeutics, Inc $6,081 3 payments
  9. Cerapedics, Inc. $5,589 10 payments
  10. Synthes GmbH $3,529 4 payments
  11. Other $10,179 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $370,255 52 payments
  2. Consulting Fee $174,571 29 payments
  3. Travel and Lodging $124,776 136 payments
  4. Food and Beverage $13,345 192 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $6,978 2 payments
  6. Honoraria $6,750 2 payments
  7. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $750 1 payment
  8. Entertainment $498 4 payments
  9. Education $111 2 payments
Products named General payments · program years 2019–2025
  1. OPTIMESH EXPANDABLE INTERBODY FUSION SYSTEM $21,036 14 payments
  2. AXOGUARD NERVE PROTECTOR $19,350 14 payments
  3. AxoGuard Nerve Connector $19,350 14 payments
  4. Medical Instrumentation $8,445 1 payment
  5. Spine $7,854 2 payments
  6. Exparel $6,750 2 payments
  7. Avance Nerve Graft $6,594 8 payments
  8. SPRINT PNS System $6,081 3 payments
  9. I-FACTOR PEPTIDE ENHANCED BONE GRAFT $5,589 10 payments
  10. KOSELUGO $3,100 1 payment
  11. Other $4,292 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

32

Median for Neurosurgery: 83

Drug cost

$49

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Hcl Generic 32 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$118,964

Medicare's payments for the services billed

Medicare patients

183

Average age 72

Services billed

599

74 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Depression 34%
Diabetes 30%
Ischemic heart disease 26%
Chronic kidney disease 20%
Osteoporosis 16%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

420 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record